The present invention is to provide a stabilized pharmaceutical composition for oral use containing 1-ethyl methylester 4-[[3-[p-(carboxyamidino)phenyl]-2-oxo-5-oxazolidinyl]meth yl]-1-piperazineacetate or a pharmaceutically acceptable salt thereof having an antagonistic action to GPIIb/IIIa receptor and an oily base. The present invention is to further provide a method for the manufacture of a stabilized pharmaceutical composition for oral use by compounding 1-ethyl methylester 4-[[3-[p-(carboxyamidino)phenyl]-2-oxo-5-oxazolidinyl]meth yl]-1-piperazineacetate or a pharmaceutically acceptable salt thereof with an oily base. The present invention is to furthermore provide a method for the stabilization of a pharmaceutical composition by compounding 1-ethyl methylester 4-[[3-[p-(carboxyamidino)phenyl]-2-oxo-5-oxazolidinyl]-met hyl]-1-piperazineacetate or a pharmaceutically acceptable salt thereof with an oily base.
As a negatively charged lipid that can stably add negative charges to the surface of vesicles without side effects, the carboxyl acid-type lipid of the following general formula [1]:
[wherein R1, R2 and R3 represent substituents of which one is represented by the following general formula [X]:
(wherein M is a hydrogen atom or monovalent cation, and m is an integer of 1 to 5 that represents the methylene chain length), and the other two are chained hydrocarbon groups; A1, A2 and A3 are the same or different substituents selected from the group consisting of C(O)O, CONH or NHCO; and n is an integer of 1 to 3 that represents the methylene chain length] is provided.
As a negatively charged lipid that can stably add negative charges to the surface of vesicles without side effects, the carboxyl acid-type lipid of the following general formula [1]
1
[wherein R
1
, R
2
and R
3
represent substituents of which one is represented by the following general formula [X]:
2
(wherein M is a hydrogen atom or monovalent cation, and m is an integer of 1 to 5 that represents the methylene chain length), and the other two are chained hydrocarbon groups; A
1
, A
2
and A
3
are the same or different substituents selected from the group consisting of C(O)O, CONH or NHCO; and n is an integer of 1 to 3 that represents the methylene chain length) is provided.
作为一种可在囊泡表面稳定添加负电荷且无副作用的负电荷脂质,以下通式的羧酸型脂质[1]
1
其中 R
1
, R
2
和 R
3
代表其中一个由以下通式表示的取代基[X]:
2
(其中 M 为氢原子或一价阳离子,m 为 1 至 5 的整数,代表亚甲基链长 度),另外两个为链状烃基; A
1
, A
2
和 A
3
是相同或不同的取代基,选自由 C(O)O、CONH 或 NHCO 组成的组,n 是 1 至 3 的整数,表示亚甲基链长 度)。
379. Wool wax. Part I. Synthesis of some anteiso-acids
作者:J. R. Nunn
DOI:10.1039/jr9510001740
日期:——
Synthesis of 1-Monoglycerides Having C11-20 Branched Chain Fatty Acids and Their Hemolysis Effects.